Polycythemia Vera Polycythemia Vera Cancer Cluster Investigation in Northeast Pennsylvania A Feasibility Assessment to Improve the Reporting of Hematopoietic Diseases

First Page		Document Content
Date: 2014-12-23 14:13:37 Cancer registry Demography Oncology Disease registry Myeloproliferative disease Agency for Toxic Substances and Disease Registry Cancer Polycythemia vera Essential thrombocytosis Medicine Medical informatics Hematopathology		Polycythemia Vera Polycythemia Vera Cancer Cluster Investigation in Northeast Pennsylvania A Feasibility Assessment to Improve the Reporting of Hematopoietic Diseases Add to Reading List Source URL: www.atsdr.cdc.gov Download Document from Source Website File Size: 108,33 KB Share Document on Facebook

	1 Dr James Vardiman Professor Emeritus Department of Pathology University of Chicago DocID: 1o8ES - View Document
	Molecular Diagnosis of Myeloid Neoplasias and Solid Tumors First report of mutations detected in the gene for NF-E2 Technology Myeloproliferative Neoplasms (MPN) are a group of several distinct, but clinically related ma DocID: 1adts - View Document
	Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: Stage 1 results Srdan Verstovsek1, Ruben Mesa2, Lynda Foltz3, Vikas Gupta4, John Mascarenhas5, Ellen Ritchie6, Ronald Hoffman5, Richard DocID: 19YPO - View Document
	Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca DocID: 19fx5 - View Document
	Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results S. Verstovsek1, R. Mesa2, L. Foltz3, V. Gupta4, J. Mascarenhas5, E. Ritchie6, R. Hoffman5, R. Silver6, W. J. Hong8, M. Kre DocID: 19eKj - View Document